Lecithins.

Lecithins are a mixture of phospholipids in which phosphatidylcholine carries choline in a fat bound form, and gut and liver phospholipases release that choline for normal methyl group and acetylcholine metabolism. Pairing lecithins with free choline gives one slow phospholipid bound pool and one rapidly available pool of the same nutrient.

Curcuminoids are poorly water soluble, and complexing them with lecithin phospholipids forms a phytosome that disperses in bile micelles instead of passing through unabsorbed. This is a formulation effect on how much curcumin reaches circulation, not a separate biological action.

Lecithin is an amphiphilic emulsifier, so it lowers the interfacial tension between an oil phase and gut fluid and helps long chain fatty acids form the mixed micelles that carry them across the intestinal wall. It also keeps the oil evenly dispersed in a softgel or emulsion instead of separating.

Lecithin is rich in polyunsaturated fatty acid chains that oxidise once exposed to air and light. Tocopherols sit in the same lipid layer and interrupt the chain reaction by donating a hydrogen to peroxyl radicals, which is why they are the usual companion antioxidant in phospholipid preparations.

Lecithins are mixed phospholipid fractions whose main component is phosphatidylcholine. A purified phosphatidylcholine ingredient overlaps with them rather than adding a distinct one.

Cholecalciferol needs a lipid phase and bile salt micelles to reach the enterocyte. Phospholipid emulsifiers reduce droplet size and keep the vitamin dispersed.

Retinyl esters partition into lipid droplets before micellar uptake. Lecithins supply the surfactant that keeps that dispersion stable.

MK-7 is strongly lipophilic and its uptake depends on micelle formation. A phospholipid emulsifier helps that step.

Ubiquinone is a large lipophilic molecule with low aqueous solubility, so absorption tracks the quality of its lipid dispersion. Phospholipid emulsifiers raise that dispersion.

Astaxanthin crystals need a lipid vehicle to enter micelles. Lecithins hold the carotenoid in that phase through digestion.

Xanthophyll uptake rises with co-ingested lipid and emulsifier. Lecithins lower droplet size so more lutein reaches the micellar phase.

Choline released from phospholipid is oxidised to betaine before donating a methyl group. Adding betaine directly leaves more choline available for membrane synthesis.

Homocysteine remethylation runs through either the folate route or the betaine route fed by choline. Folate adequacy lowers the draw on the choline pool.

Both ingredients feed the same free choline pool. Their choline contributions add together in a formula rather than counting separately.

Biliary phospholipid and bile salts work together to emulsify dietary fat, and supplemental lecithin adds to the same emulsifying pool in the duodenum. Where bile output is limited, the emulsion is coarser and fat digestion slows. The two components act at the same interface for the same purpose.

Lecithin stabilises fine oil droplets, and it is the surface area of those droplets that pancreatic lipase acts on. More interface means faster triglyceride hydrolysis. The pairing is a digestion-side relationship rather than a systemic one.

Pancreatin supplies phospholipase A2 as well as lipase, and phospholipase A2 is the enzyme that cleaves phosphatidylcholine at the sn-2 position to lysophosphatidylcholine and a free fatty acid. That cleavage is the step that makes dietary lecithin absorbable. The two are sequential parts of one process.

A blend carrying lipase and phospholipase acts on the emulsion that lecithin creates, and lecithin in turn increases the interface those enzymes need. The relationship runs in both directions within normal fat digestion.

CDP-choline is the activated intermediate of the Kennedy pathway, the main route by which cells build phosphatidylcholine. Dietary lecithin supplies both preformed phosphatidylcholine and the choline that feeds that pathway. They converge on the same membrane phospholipid pool from different points.

The liver makes phosphatidylcholine by a second route in which PEMT methylates phosphatidylethanolamine three times, and each methyl group comes from S-adenosylmethionine. SAM availability therefore sets the capacity of that route. Lecithin supplies the product of the pathway directly.

Methionine is the precursor of S-adenosylmethionine, the methyl donor for the PEMT route to phosphatidylcholine. When methionine is short, that route contributes less and dietary phosphatidylcholine carries more of the load. This is settled one-carbon biochemistry.

B12 is the cofactor for methionine synthase, which remethylates homocysteine back to methionine and so sustains the SAM pool used for phosphatidylcholine methylation. Poor B12 status shifts the burden of choline and betaine within the same cycle. The link is a recognised cofactor relationship.

Commercial lecithin is a mixture that contains phosphatidylinositol alongside phosphatidylcholine and phosphatidylethanolamine, and inositol is the head group of that fraction. Supplemental inositol feeds the same head-group pool used to build membrane phosphoinositides. This is a compositional and pathway overlap.

Phosphatidylserine is made by base exchange from phosphatidylcholine or phosphatidylethanolamine, both of which lecithin supplies. The three phospholipids interconvert within the same membrane biosynthetic network. Supplements of either land in that shared pool.

Soy and sunflower lecithin carry linoleic acid as the dominant fatty acid esterified at the sn-2 position of their phospholipids. Digesting that lecithin releases linoleic acid along with lysophosphatidylcholine. The overlap is compositional and worth stating on a label rather than being a separate effect.

Krill oil is itself a phospholipid preparation, with EPA and DHA esterified onto phosphatidylcholine rather than triglyceride. It and lecithin therefore enter the same phospholipase-driven digestion route. Stacking the two raises total phospholipid intake rather than adding a distinct mechanism.

Phospholipid-bound DHA follows the lysophospholipid absorption route and is the form enriched in neural membranes. Lecithin provides the phospholipid backbone that DHA can be esterified onto during re-acylation in the enterocyte. The pairing concerns how the fatty acid is carried, not how much is present.

Lecithin phospholipids are rich in polyunsaturated fatty acids and oxidise on the shelf, producing off flavours and lysophospholipids. Tocopherols are the usual chain-breaking antioxidant included to slow that. The relationship protects the lecithin itself.

Carotenoid uptake depends on incorporation into mixed micelles, and phospholipid emulsifiers increase the fine dispersion of the oil phase that feeds those micelles. Food and formulation studies describe better dispersion of carotenoids in phospholipid-containing systems. The measured endpoint is usually plasma concentration, which is a marker.

Lycopene is crystalline and poorly dispersible, and phospholipid emulsions are one of the standard ways of getting it into a fine oil phase. Better dispersion supports micellar solubilisation in the gut. The effect described is on delivery rather than on a clinical endpoint.

Phylloquinone is highly lipophilic and its uptake tracks the fat content and emulsification of the meal it arrives with. A phospholipid emulsifier supplies that interface in a capsule format. This is the same micellar dependence shared by all fat-soluble vitamins.

Quercetin aglycone dissolves poorly in water, and complexing it with phospholipid is a recognised way to raise its apparent solubility and membrane partitioning. The resulting phospholipid complex is what most phytosome-style products use. Reported gains are in measured plasma concentrations, a marker rather than an outcome.

Silybin has very low aqueous solubility, and the phospholipid complex format was developed specifically to address that. Lecithin-derived phosphatidylcholine is the complexing partner in those preparations. What improves is the amount reaching the circulation, which is a pharmacokinetic marker.

Berberine is absorbed poorly and phospholipid complexation is one of the delivery approaches applied to it. The phospholipid changes partitioning across the intestinal membrane rather than changing the molecule. Evidence here is formulation pharmacokinetics, not a clinical comparison.

Boswellic acids are lipophilic and poorly absorbed, and lecithin-based complexes are used commercially to raise their measured plasma levels. The phospholipid acts as a carrier at the absorption step. This describes delivery, not an effect in the body.

Resveratrol has low water solubility and heavy first-pass conjugation, and phospholipid or liposomal carriers are among the formulation responses to that. Lecithin supplies the phospholipid for those carriers. The relationship is a delivery one and the endpoints reported are pharmacokinetic.

Pterostilbene is the dimethylated stilbene analogue and is more lipophilic than resveratrol, so it partitions readily into a phospholipid phase. Lecithin-based carriers are used on that basis. Evidence for the pairing sits at the formulation level.

Calcium ions bind free fatty acids released during fat digestion and form poorly absorbed calcium soaps, and they also bridge anionic phospholipid head groups. Large calcium doses in the same meal therefore work against emulsion stability and fat uptake. Spacing the doses is the usual practical answer.